CClinicalTrials.gg
Sign In
Status unknownNCT01630174Updated Jun 28, 2012

IMRT/Pemetrexed/Cisplatin in Esophageal Cancer

An observational study in Esophageal Cancer, sponsored by Shandong Cancer Hospital and Institute. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-06-28.

Sponsored by Shandong Cancer Hospital and Institute · Observational

The sponsor has not verified this record recently (last verified Jun 2012), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To evaluate the effect of concomitant late course accelerated hyperfractionation radiochemotherapy with pemetrexed and cisplatin in patients with esophagus cancer

02

Conditions studied

  • Esophageal Cancer

Keywords

  • IMRT,Pemetrexed,Cisplatin , Esophageal Cancer
03

In context

Esophageal Neoplasms

1,593 studies on the registry are indexed under Esophageal Neoplasms; 461 are open to participants now.

This study's planned enrollment of 30 is below the median of 200 across 341 observational studies indexed under Esophageal Neoplasms.

Browse Esophageal Neoplasms studies →

Lead sponsor

Shandong Cancer Hospital and Institute is the lead sponsor of 103 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

esophagus cancer patients

Inclusion criteria

  1. Signed informed consent; 2.Acquired pathological diagnosis; 3.Life expectancy≥6 months; 4.Age:18-75 years, male or female; 5.General state of health: ECOG 0-1 grade; 6.Without any chemotherapy or radiotherapy; 7.Subjects meet the following criteria for the clinical laboratory:HG≥100g/L, WBC≥3.5X109 /L, neutrophilic leukocyte≥1.5X109,PLT100X109 /L。CR≤1.5 x N，TB≤2.5XN，AST and ALT≤2.5xN，AKP≤2.5XN.

Exclusion criteria

Exclusion Criteria:

  • 1.Serious infection; 2.Uncontrollable diabetes; 3.Other serious diseases, such as myocardial infarction in 6 months; 4. Participated other clinical trials in 4 weeks or at present
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
06

Study locations

1 of 1 sites recruiting
  • Shandong Cancer hospital and institute
    Jinan, Shandong 250017, China
    • Baosheng Li, Ph.D. · Principal investigator
    • Zhongtang Wang, M.D. · Sub investigator
    Recruiting
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT01630174
Lead sponsor
Shandong Cancer Hospital and Institute
Responsible party
Baosheng Li (Ph.D., Shandong Cancer Hospital and Institute) — Principal investigator
First posted
Jun 28, 2012
Start date
Oct 2009
Last update
Jun 28, 2012

Study contacts

Zhongtang Wang, M.D.
Contact
wangzt0528@163.com
+86.531.67626162

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Esophageal Neoplasms→

Other studies from this sponsor

Shandong Cancer Hospital and Institute

Start the discussion